Therefore, our aim was to quantify tissue CPs in vivo during CKD evolution in a mouse model of subtotal (75%) surgical kidney reduction to demonstrate CP accumulation in tissues during CKD and thus provide new arguments in favour of the involvement of carbamylation in CKD complications. Here, CAD is linked to chronic kidney disease.